Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – N-c doai
Reexamination Certificate
2005-03-15
2005-03-15
Nickol, Gary B. (Department: 1642)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
N-c doai
C514S183000, C424S078140
Reexamination Certificate
active
06867231
ABSTRACT:
A compound comprising a target cell-specific portion and human NAD(P)H:quinone reductase 2 (NQO2) or a variant or fragment or fusion or derivative thereof which has substantially the same activity as NQO2 towards a given prodrug, or a polynucleotide encoding said NQO2 or said variant or fragment or fusion or derivative. A recombinant polynucleotide comprising a target cell-specific promoter operably linked to a polynucleotide encoding human NAD(P)H:quinone reductase 2 (NQO2) or a variant or fragment or fusion or derivative thereof which has substantially the same activity as NQO2 towards a given prodrug. The compounds and polynucleotides are useful in a method of treating a patient in conjunction with a suitable prodrug. A method of treating a human patient with a target cell to be destroyed wherein the target cell expresses NQO2 the method comprising administering to the patient a prodrug which is converted to a substantially cytotoxic drug by the action of NQO2 and nicotinamide riboside (reduced) (NRH) or an analogue thereof which can pass reducing equivalents to NQO2.
REFERENCES:
patent: 4440859 (1984-04-01), Rutter et al.
patent: 4530901 (1985-07-01), Weissmann
patent: 4582800 (1986-04-01), Crowl
patent: 4677063 (1987-06-01), Mark et al.
patent: 4678751 (1987-07-01), Goeddel
patent: 4704362 (1987-11-01), Itakura et al.
patent: 4710463 (1987-12-01), Murray
patent: 4757006 (1988-07-01), Toole, Jr. et al.
patent: 4766075 (1988-08-01), Goeddel et al.
patent: 4810648 (1989-03-01), Stalker
patent: 0 251 744 (1988-01-01), None
patent: 0 258 067 (1988-03-01), None
patent: 0 302 473 (1989-02-01), None
patent: 0 415 731 (1991-03-01), None
patent: WO 8807378 (1988-10-01), None
patent: WO 8910140 (1989-11-01), None
patent: WO 9001063 (1990-02-01), None
patent: WO 9109867 (1991-07-01), None
patent: WO 9111201 (1991-08-01), None
patent: WO 9308288 (1993-04-01), None
patent: WO 9313805 (1993-07-01), None
patent: WO 9313806 (1993-07-01), None
patent: WO 9512678 (1995-05-01), None
patent: WO 9707097 (1997-02-01), None
patent: WO 9720580 (1997-06-01), None
patent: WO 9724143 (1997-07-01), None
patent: WO 9822577 (1998-05-01), None
patent: WO 9824478 (1998-06-01), None
Friedlos et al. (Biochem. Pharmacol. 44(9) pp. 1739-43, 1992, IDS).*
Jaiswal, A. (J.Biol.Chem. 269(20), pp. 14502-08, 1994, IDS).*
Freshney, Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p4.*
Dermer (Bio/Technology, 1994, 12:320).*
Gura (Science, v278, 1997, pp. 1041-1042).*
Anlezark, et al., “The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)--1, Purification and properties of a nitroreductase enzyme from Escherichia coli--a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT),”Biochem. Pharmacol. 1992 44(12):2289-95.
Better, et al., “Escherichia coli secretion of an active chimeric antibody fragment,”Science240(4855):1041-43 (1988).
Bird, et al., “Single-chain antigen-binding proteins,”Science242(4877):423-26 (1988).
Bischoff, et al., “An adenovirus mutant that replicates selectively in p53-deficient human tumor cells,”Science274(5286):373-76 (1996).
Boland, et al., “The differences in kinetics of rat and human DT diaphorase result in a differential sensitivity of derived cell lines to CB 1954 (5-(aziridin-1yl)-2,4-dinitrobenzamide),”biochem. Pharmacol. 41(6-7):867-75 (1991).
Bradl, et al., “Malignant melanoma in transgenic mice,”Proc. Natl. Acad. Sci. U. S. A.88(1):164-68 (1991).
Brawer, “Prostate specific antigen. A review,”Acta. Oncol. 30(2):161-68 (1991).
Chen, et al., “Expression of rat liver NAD(P)H:quinone-acceptor oxidoreductase in Escherichia coli and mutagenesis in vitro at Arg-177,”Biochem. J. 284 (Pt3):855-60 (1992).
Chen, et al., “Molecular basis of the catalytic differences among DT-diaphorase of human, rat, and mouse,”J. Biol. Chem. 272(3):1437-39 (1997).
Clark, et al., “Role of the Bp35 cell surface polypeptide in human B-cell activation,”Proc. Natl. Acad. Sci. U. S. A.82(6):1766-70 (1985).
Connors & Wisson, “Cure of mice bearing advanced plasma cell tumours with aniline mustard: the relationship between glucuronidase activity and tumour sensitivity,”Nature210(38):866-67 (1966).
Corvalan & Smith, “Construction and characterisation of a hybrid-hybrid monoclonal antibody recognising both carcinoembryonic antigen (CEA) and virnca alkaloids,”Cancer Immunol. Immunother. 24(2):127-32 (1987).
Corvalan, et al., “Increased therapeutic effect of vinca alkaloids targeted to tumour by a hybrid-hybrid monoclonal antibody,”Cancer Immunol. Immunother. 24(2):138-43 (1987).
Corvalan, et al., “Specific in vitro and in vivo drug localisation to tumour cells using a hybrid-hybrid monoclonal antibody recognising both carcinoembryonic antigen (CEA) and vinca alkaloids,”Cancer Immunol. Immunother. 24(2):133-37 (1987).
Cotten, et al., “High-efficiency receptor-mediated delivery of small and large (48 kilobase gene constructs using the endosome-disruption activity of defective or chemically inactivated adenovirus particles,”Proc. Natl. Acad. Sci. U. S. A.89(13):6094-98 (1992).
Coussens, et al., “Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene,”Science230(4730):1132-39 (1985).
Culver, et al., “In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors,”Science256(5063):1550-52 (1992).
Curiel, “Adenovirus facilitation of molecular conjugate-mediated gene transfer,”Prog. Med. Virol. 40:1-18 (1993).
Drabek, et al., “The expression of bacterial nitroreductase in transgenic mice results in specific cell killing by the prodrug CB1954,”Gene Ther.4(2):93-100 (1997).
Friedlos & Knox, “Metabolism of NAD(P)H by blood components. Relevance to bioreductively activated prodrugs in a targeted enzyme therapy system,”Biochem. Pharmacol.44(4):631-35 (1992).
Friedlos, et al., “Identification of novel reduced pyridinium derivatives as synthetic co-factors for the enzyme DT diaphorase (NAD(P)H dehydrogenase (quinone), EC 1.6.99.2),”Biochem. Pharmacol.44(1):25-31 (1992).
Friedlos, et al., “Potentiation of CB 1954 cytotoxicity by reduced pyridine nucleotides in human tumour cells by stimulation of DT diaphorase activity,”Biochem. Pharmacol.44(9):1739-43 (1992).
Gilliland, et al., “Universal bispecific antibody for targeting tumor cells for destruction by cytotoxic T cells,”Proc. Natl. Acad. Sci. U. S. A.85(20):7719-23 (1988).
Green, et al., “Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retrovital transduction and expression of the E. coli nitroreductase gene,”Cancer Gene Ther.4(4):229-38 (1997).
Harwood, et al., “Comparative tumour localization of antibody fragments and intact lgG in nude mice bearing a CEA-producing human colon tumour xenograft,”Eur. J. Cancer Clin. Oncol.21(12):1515-22 (1985).
Hellström, et al., “Monoclonal mouse antibodies raised against human lung carcinoma,”Cancer Res.46(8):3917-23 (1986).
Hurrell, “Monoclonal Hybridoma Antibodies: Techniques and Applications,” (CRC Press).
Huston, et al., “Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli,”Proc. Natl. Acad. Sci. U. S. A.85(16):5879-83 (1988).
Jackson, et al., “The tyrosinase-related protein-1 gene has a structure and promoter sequence very different from tyrosinase,”Nucleic Acids Res.19(14):3799-804 (1991.
Jaiswal, “Human Nad(P)H:quinone oxidoreductase2. Gene structure, activity, and tissue-specific expression,”J. Biol. Chem.269(20):14502-08 (1994).
Jaiswal, “Nucleotide and deduced am
Burke Philip John
Knox Richard John
Enzacta R & D Limited
Holland & Knight LLP
Nickol Gary B.
LandOfFree
Therapeutic systems does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic systems, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic systems will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3420894